You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Starting in late 2020, public health insurance is expected to pay for NIPT if a trisomy is suspected and this constitutes an "unacceptable burden" for the pregnant woman.
In addition, a German court found in December that German NIPT company Cenata infringes Streck's patent.
Streck claims that the blood collection tubes in the Roche Ariosa Harmony kit that Cenata uses infringe its patent.
Until March 2018, when the patent in question expires, Cenata will have its Harmony test performed by Medirex in Slovakia.
Last week, the G-BA, a committee that decides about reimbursable medical services in Germany, said it will start a methods evaluation of noninvasive prenatal testing.
Several new laboratories started to offer NIPT locally in 2015, and some providers have been shifting to less-expensive non-NGS platforms.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.